Overview
ology clinical trial was designed to evaluate safety, tolerability, dose escalation, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity.
Novotech provided full-service clinical trial support, including regulatory strategy, study start-up, and cross-regional project management. Leveraging it integrated operating model and strong regulatory expertise, the team successfully navigated complex GMO regulatory requirements, securing approvals from multiple oversight bodies while implementing early at-risk activities to accelerate timelines for this first-in-human study.
Through close collaboration with the sponsor and coordinated execution across regional teams, Novotech activated Australian sites despite limited availability of FIH GMO-experienced centers and achieved rapid start-up momentum for this innovative solid tumor clinical trial.
The Challenge
Launching a first-in-human oncology study involving a genetically modified organism presents significant regulatory and operational complexity.
Key challenges included:
- Navigating multi-layered GMO regulatory oversight, including biosafety and genetic technology approvals
- Managing parallel regulatory pathways across Australia and the United States
- Identifying and activating sites with both early-phase oncology expertise and experience managing GMO therapeutics, where availability was limited
- Maintaining study start-up momentum while ensuring compliance with evolving biosafety and regulatory requirements
The sponsor required a CRO partner with the regulatory expertise, operational agility, and oncology experience to manage these complexities while enabling a timely transition from study start-up to patient dosing.
Novotech’s Approach
Novotech implemented an integrated regulatory and operational strategy designed to streamline approvals and accelerate site activation.
Coordinated Regulatory Strategy: Novotech guided the sponsor through complex GMO regulatory pathways, coordinating submissions and approvals across relevant regulatory and biosafety oversight bodies while aligning regulatory processes with clinical trial start-up requirements.
Accelerated Study Start-Up: Early at-risk start-up activities were implemented in parallel with regulatory review to maintain study momentum and minimize delays between approvals and site activation.
Targeted Site Selection: Leveraging its established oncology network in Australia, Novotech identified investigators and clinical sites capable of supporting first-in-human oncology studies involving GMO therapeutics.
Cross-Regional Operational Alignment: A centralized project management framework ensured seamless coordination between U.S. and Australian teams, enabling efficient communication, regulatory alignment, and consistent operational execution across regions.
Outcomes
Despite the complexity of launching a first-in-human GMO oncology trial across multiple regulatory jurisdictions, Novotech successfully advanced the study from start-up to dosing.
Key outcomes included:
- Successful navigation of complex GMO regulatory requirements across multiple oversight bodies
- Activation of Australian sites despite limited availability of first-in-human GMO-experienced centers
- Achievement of First Patient First Dose (FPFD) on 2 December 2025
- Rapid start-up momentum supporting global study execution
Study footprint at a glance
- Sites: 6 planned total (Australia 3; United States 3)
- Activated sites: 2 in Australia
- First Patient First Dose (FPFD): 2 December 2025
- Recruitment target: 42 patients (Australia 23; United States 19)